Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Surefire Medical enrolls patients in COSY clinical trial to investigate benefits of SIRT in liver metastasis

Surefire Medical, Inc. today announced that it has completed enrollment in the Coiling vs. Surefire Infusion System in Y90 (COSY) clinical trial.

11 Dec 2013

Daiichi Sankyo presents subgroup analysis of Hokusai-VTE study at ASH annual meeting

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced results of a prespecified subgroup analysis of 771 cancer patients enrolled in the phase 3 Hokusai-VTE study.

11 Dec 2013

Study shows children with ALL can safely receive intravenous infusions of chemotherapy

Children with acute lymphoblastic leukemia (ALL), the most common form of pediatric cancer, can safely receive intravenous infusions of a reformulated mainstay of chemotherapy that has been delivered via painful intramuscular injection for more than 40 years, research suggests.

11 Dec 2013

Budget cuts, years-long flat funding can delay research into effective treatments for cancer

Research advances that have come to fruition over the past year demonstrate extraordinary progress in the fight against cancer, according to a new report released today by the American Society of Clinical Oncology. The report stresses, however, that recent budget cuts and years-long flat funding can only delay efforts to translate research into effective treatments for millions of individuals with cancer.

11 Dec 2013

Antibody-toxin compound shows compelling antitumor activity in non-Hodgkin lymphomas patients

A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute.

11 Dec 2013

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

ProNAi Therapeutics, Inc., a leader in developing nucleic acid therapeutics, presented safety and efficacy data from its ongoing Phase II study yesterday at the 55th Annual Meeting of the American Society for Hematology (ASH) in New Orleans, Louisiana.

11 Dec 2013

Nanostring Technologies announces nationwide availability of Prosigna Breast Cancer Assay in 2014

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced nationwide availability of the Prosigna™ Breast Cancer Prognostic Gene Signature Assay beginning in the first quarter of 2014.

From NanoString Technologies 11 Dec 2013

Discovery could lead to new way to combat cancer

One way to defeat an opponent is to cut off its supply lines. Tumors are no different. The supply lines for tumors are the blood vessels that ferry oxygen and nutrients to the cells. Restricting the blood vessels that feed tumor cells can shrink the tumor. A cross-institutional international team of scientists recently discovered a new, important step of the process that grows new blood vessels, a discovery that could lead to a new way to combat cancer.

11 Dec 2013

Echo Therapeutics signs strategic collaboration agreement with MTIA

Echo Therapeutics, Inc., a medical device company developing its Symphony CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it entered into a strategic collaboration agreement with Medical Technologies Innovation Asia, Ltd., Hong Kong, for a license arrangement and equity investment in Echo.

10 Dec 2013

Pemetrexed, paclitaxel regimens equally effective in NSCLC

PointBreak trial results suggest that pemetrexed- and paclitaxel-based chemotherapy offer comparable survival outcomes and tolerability for patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) but with differing toxicity profiles.

10 Dec 2013

Biosimulation and epilepsy treatments: an interview with Dr. Serge Bischoff, CEO of Rhenovia and RHENEPI program director

The need for biosimulation is primarily to do with the very high attrition rate in drug development and especially in the development of drugs for the central nervous system.

10 Dec 2013

Reverse Medical gets FDA clearance to market MVP-5 Micro Vascular Plug system in the US

Reverse Medical Corporation today announced FDA clearance for US commercialization of their MVP-5 Micro Vascular Plug system for peripheral vessel embolization, and the first US clinical case. The MVP-5 system is indicated for use to obstruct or reduce the rate of blood flow in the peripheral vasculature, in vessels measuring between 3.0 and 5.0 mm.

10 Dec 2013

COC launches first clinic on London's Harley Street for specialised cancer treatment

Care Oncology Clinic, an independent, private organisation providing oncology treatments, announces today the launch of its first clinic on London's Harley Street. Delivered by leading oncologists and palliative care doctors, the clinic is the first of its kind, specifically set up to offer a specialised cancer treatment by targeting the energy requirements of cancer cells using existing medicines that are already licensed for this purpose, have an acceptable safety profile and are low cost. Designed for patients for whom the standard oncology treatment regime is not available, viable, tolerable or providing benefit, this is a new option for treating these cancer patients.

10 Dec 2013

ACoS Commission on Cancer, PHCQA partner to make PA cancer quality data available to public

The American College of Surgeons Commission on Cancer has joined with the Pennsylvania Health Care Quality Alliance to make cancer quality data from participating Pennsylvania hospitals available to the public. The initiative, which is the first of its kind in the U.S., will include data from 72 percent (52 programs) of all CoC-accredited cancer programs in Pennsylvania.

10 Dec 2013

Researchers identify 10 genes that may signify trifecta of benefits for women with ovarian cancer

Researchers in the Women's Cancer Program at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute have identified a series of 10 genes that may signify a trifecta of benefits for women diagnosed with ovarian cancer and ultimately reflect improved survival outcomes.

10 Dec 2013

Takeda presents clinical study results of oral proteasome inhibitor MLN9708 in multiple myeloma patients

Takeda Pharmaceutical Company Limited today announced final Phase 1 and preliminary Phase 2 results of a study combining oral investigational MLN9708 administered twice a week with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

10 Dec 2013

CRAB CTC enrolls first patient into inaugural cancer clinical trial

Cancer Research And Biostatistics today announced enrollment of the first patient into the inaugural clinical trial sponsored by its Clinical Trials Consortium. The CRAB CTC mission is to ensure rapid clinical testing of new and innovative cancer treatments, and is focusing on lung cancer as its first target. By engaging frontline treating oncologists to push the boundaries of patient care, the aim is to improve the standard of care and extend overall survival.

9 Dec 2013

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase inhibitors for enhanced therapeutic outcomes, today announced that positive interim clinical data from the two proof-of-concept clinical trials with selective HDAC6 inhibitor, ricolinostat (ACY-1215), were presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans, LA.

9 Dec 2013

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States Food and Drug Administration voted to recommend approval of Takeda's vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease.

9 Dec 2013

Arrowhead reports Phase 1 study data on ARC-520 for treatment of chronic hepatitis B infection

Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that COO and Head of R&D, Bruce Given, M.D., presented data on the Phase 1 clinical study of ARC-520, the company's clinical candidate for the treatment of chronic hepatitis B infection, at the HepDART 2013 conference being held on The Big Island, Hawaii.

9 Dec 2013

Oncology News and Research

Further Reading

Surefire Medical enrolls patients in COSY clinical trial to investigate benefits of SIRT in liver metastasis

Daiichi Sankyo presents subgroup analysis of Hokusai-VTE study at ASH annual meeting

Study shows children with ALL can safely receive intravenous infusions of chemotherapy

Budget cuts, years-long flat funding can delay research into effective treatments for cancer

Antibody-toxin compound shows compelling antitumor activity in non-Hodgkin lymphomas patients

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

Nanostring Technologies announces nationwide availability of Prosigna Breast Cancer Assay in 2014

Discovery could lead to new way to combat cancer

Echo Therapeutics signs strategic collaboration agreement with MTIA

Pemetrexed, paclitaxel regimens equally effective in NSCLC

Biosimulation and epilepsy treatments: an interview with Dr. Serge Bischoff, CEO of Rhenovia and RHENEPI program director

Reverse Medical gets FDA clearance to market MVP-5 Micro Vascular Plug system in the US

COC launches first clinic on London's Harley Street for specialised cancer treatment

ACoS Commission on Cancer, PHCQA partner to make PA cancer quality data available to public

Researchers identify 10 genes that may signify trifecta of benefits for women with ovarian cancer

Takeda presents clinical study results of oral proteasome inhibitor MLN9708 in multiple myeloma patients

CRAB CTC enrolls first patient into inaugural cancer clinical trial

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Arrowhead reports Phase 1 study data on ARC-520 for treatment of chronic hepatitis B infection

Cancer Research - Second Edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News